SCHEMBL2273799

SCHEMBL2273799

O=C(Nc1cc(-c2ccc(O)cc2)ccc1C(=O)O)c1nc2ccccc2s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.73
PKM P14618 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
NFKB1 P19838 2/20 0.57
RAB9A P51151 2/20 0.57
NFKB2 Q00653 2/20 0.57
RELA Q04206 2/20 0.57
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CRHBP P24387 2/20 0.51
CRHR2 Q13324 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
ACLY P53396 2/20 0.49
MAOB P27338 1/20 0.49
PRSS12 P56730 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275537 0.94 HDAC1 (0.78) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2270969 0.85 HDAC1 (0.65) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2274012 0.83 HDAC1 (0.59) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2274032 0.81 HDAC1 (0.56) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2271790 0.81 SMN1; SMN2 (0.56) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2275030 0.81 MEN1 (0.61) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2274974 0.79 ACLY (0.67) HDAC1PKMMEN1KMT2AACLY
SCHEMBL28308136 0.79 NPC1 (0.81) HDAC1PKMSMN1; SMN2NPC1NFKB1
SCHEMBL2272605 0.77 DHODH (0.73) HDAC1PKMNPC1RAB9AMEN1
SCHEMBL6833895 0.77 SMN1; SMN2 (0.55) HDAC1PKMSMN1; SMN2NPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC1 71/4885PKM 2367/4885SMN1; SMN2 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.